Real-time dose-rate monitoring with gynecologic brachytherapy: Results of an initial clinical trial.
A nanoscintillator-based fiber-optic dosimeter (nanoFOD) was developed to measure real-time dose rate during high-dose-rate (HDR) brachytherapy. A trial was designed to prospectively test clinical feasibility in gynecologic implants. A clinical trial enrolled women undergoing vaginal cylinder HDR brachytherapy. The nanoFOD was fixed to the cylinder alongside two thermoluminescent dosimeters (TLDs). Treatment was delivered and real-time dose rates captured by the nanoFOD. The nanoFOD and TLD positions were identified in CT images and used to extract the treatment planning system (TPS) calculated dose. The nanoFOD and TLD cumulative doses were compared with the TPS. Nine women were enrolled for 30 fractions, and real-time data were available in 27 treatments. The median ratio of nanoFOD/TPS dose was 1.00 (IQR 0.94-1.02), with a TLD/TPS ratio of 1.01 (IQR 0.98-1.04). Of the nanoFOD dose measurements, 63% were within 5% of the TPS, 26% between 5 and 10% of the TPS, and the remaining 11% between 10 and 20% of the TPS dose. Of the TLD measurements, 70% were within 5% of the TPS, 22% between 5 and 10% of the TPS, and 7% between 10 and 20% of the TPS dose. Real-time dose-rate measurements during HDR brachytherapy were feasible using the nanoFOD and cumulative dose per fraction showed reasonable agreement to TLD and TPS doses. Additional studies to determine dose thresholds that would yield a low false alarm rate and ongoing device development efforts to improve localization of the scintillator in CT images are needed before this detector should be used to inform clinical decisions.